Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine

Leuk Res. 2009 Jul;33(7):e81-2. doi: 10.1016/j.leukres.2008.11.030. Epub 2009 Jan 20.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use
  • Core Binding Factor Alpha 3 Subunit / genetics
  • Cytogenetic Analysis
  • DNA Helicases / genetics*
  • Decitabine
  • Humans
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Myelodysplastic Syndromes / pathology
  • Nuclear Proteins / genetics*
  • Prognosis
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA, Neoplasm / genetics
  • RNA, Neoplasm / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • X-linked Nuclear Protein

Substances

  • Antimetabolites, Antineoplastic
  • Core Binding Factor Alpha 3 Subunit
  • Nuclear Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • Runx3 protein, human
  • Decitabine
  • DNA Helicases
  • ATRX protein, human
  • X-linked Nuclear Protein
  • Azacitidine